Table 3:
Variables associated with mortality at 1-month follow-up
| Mortality (n = 7) | Survival (n = 28) | P | |
|---|---|---|---|
| Men (No.) (%) | 4 (57.1) | 19 (67.9) | .593 |
| Age (mean) (SD) (yr) | 77.43 (10.85) | 70.93 (13.1) | .235 |
| Prior antiplatelet therapy (No.) (%) | 2 (28.6) | 4 (15.4) | .422 |
| Prior anticoagulant therapy (No.) (%) | 1 (14.3) | 3 (11.5) | .843 |
| Previous use of statins (No.) (%) | 1 (14.3) | 2 (7.7) | .590 |
| Baseline NIHSS (median) (IQR) | 23 (16–24) | 7 (3–14) | <.001 |
| Baseline GCS (median) (IQR) | 10 (4–15) | 15 (15–15) | .007 |
| Systolic BP at admission (mean) (SD) (mm Hg) | 164.86 (37.9) | 169.09 (31.99) | .771 |
| Blood glucose level at admission (mean) (SD) (mg/dL) | 152 (20.14) | 133.86 (52.34) | .381 |
| Platelet count/mm3 at admission (mean) (SD) | 222,714 (89,582) | 219,840 (73,803) | .931 |
| Baseline HV measured with CT (median) (IQR) (mL) | 98.51 (80.68–124.01) | 6.85 (1.95–38.06) | <.001 |
| Baseline MLS measured with CT (median) (IQR) (cm) | 0.88 (0.56–1.48) | 0 (0–0.18) | .001 |
| Significant HG assessed with CT (No.) (%) (mL)a | 1 (100) | 1 (5.6) | .105 |
| Baseline HV measured with TDS (median) (IQR) | 59.13 (33.82–85.42) | 8.62 (3.69–21.56) | <.001 |
| Baseline MLS measured with TDS (median) (IQR) (cm) | 0.4 (0.29–1.45) | 0.09 (0.04–0.16) | .001 |
| Pulsatility index from the ipsilateral MCA (mean) (SD) (cm/s) | 1.54 (0.45) | 1.2 (0.34) | .033 |
| Pulsatility index from the contralateral MCA (mean) (SD) (cm/s) | 1.37 (0.36) | 1.12 (0.27) | .058 |
| Lobar localization (No.) (%) | 6 (85.7) | 10 (35.7) | .018 |
| IVH (No.) (%) | 4 (44.4) | 6 (23.1) | .393 |
Note:—GCS indicates Glasgow Coma Scale; IVH, intraventricular hemorrhage; BP, blood pressure; HG, hematoma growth.
a
Analysis was restricted to 21 patients for whom a follow-up CT scan was available.